ELTP — ELITE PHARMACEUTICALS INC /NV/

OTC · Health Care · Pharmaceuticals · CIK 1053369 ·
Last close
$0.35
Market Cap
$373.39M
52W High
$0.41
52W Low
$0.33
ADV30
511,776
Next earnings
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. In addition, the company provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with sequestered Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. Additionally, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 31,589,251 12,953,175 9,012,943 18,593,806 126,412,637 21,094,904 46,098,554
Sep 2025 36,321,704 14,073,033 8,213,746 13,702,407 117,247,811 26,617,346 55,662,843
Jun 2025 40,211,097 27,225,970 21,699,707 -5,884,715 111,339,370 21,737,797 63,656,727
Mar 2025 31,996,273 17,295,108 12,757,085 16,997,737 96,387,477 11,315,385 42,872,448

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$18,519,746
Investing CF
$-1,281,720
Financing CF
$-4,417,831
CapEx
$-1,281,720
Dividends Paid
Buybacks
EPS Diluted TTM
$0.00
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-94,292,428
Inventory
$25,099,135
Receivables
$48,529,574
ST Investments
EBIT TTM
$55,742,191
Pretax Income TTM
$55,231,748
Interest Exp TTM
$510,443
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$140,118,320
EBITDA
$53,271,232
Free Cash Flow
$-474,370
Enterprise Value
$357,029,760
Total Cash
$21,094,904
Total Debt
$6,056,957
Shares Out
1,076,996,442
Trailing EPS
$0.04
Book Value
$0.07
ROE
74.4%
ROA
29.7%
Div Yield

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2025 84,043,929 21,203,894 -4,314,659 96,387,477 42,872,448 7,455,639
Mar 2024 56,625,128 10,788,769 20,108,631 83,653,536 26,070,718 -3,235,115
Mar 2023 34,155,114 3,968,809 3,561,846 40,896,018 11,935,758 3,338,704

Peers — same industry

TickerNameMarket CapLastDaily %
VNDA Vanda Pharmaceuticals Inc. $374.04M $6.22
PBYI PUMA BIOTECHNOLOGY, INC. $370.04M $7.27
GLSI Greenwich LifeSciences, Inc. $379.48M $27.39
LYEL Lyell Immunopharma, Inc. $381.98M $16.37
VSTM Verastem, Inc. $383.13M $4.36

News headlines (Yahoo Finance, 1h cache)

Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets
2026-04-02 12:00 · Yahoo
The Zacks Analyst Blog Highlights GE Aerospace, Shell, McKesson, Elite Pharmaceuticals and Geospace Technologies
2026-03-18 14:23 · Yahoo
Top Stock Reports for GE Aerospace, Shell & McKesson
2026-03-17 20:10 · Yahoo
Elite Pharmaceuticals Inc (ELTP) Q3 2026 Earnings Call Highlights: Record Revenue Surge and ...
2026-02-24 01:00 · Yahoo
Elite Pharmaceuticals Stock Dips Post Q3 Earnings Despite Revenue Jump
2026-02-20 15:57 · Yahoo
Elite Pharmaceuticals Q3 Earnings Call Highlights
2026-02-19 05:07 · Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information
2026-02-17 21:19 · Yahoo
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026
2026-02-11 21:30 · Yahoo
ELTP Stock Declines Despite Solid Q2 Earnings and Revenue Performance
2025-11-19 16:37 · Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information
2025-11-14 21:19 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.